Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

Open access
Kjaer, Susanne K., Sigurdsson, Kristján, Iversen, Ole-Erik, Hernandez-Avila, Mauricio, Wheeler, Cosette M., Perez, Gonzalo, Brown, Darron R., Koutsky, Laura A., Tay, Eng Hseon, García, Patricia, Ault, Kevin A., Garland, Suzanne M., Leodolter, Sepp, Olsson, Sven-Eric, Tang, Grace W.K., Ferris, Daron G., Paavonen, Jorma, Lehtinen, Matti, Steben, Marc, Bosch, F. Xavier, Dillner, Joakim, Joura, Elmar A., Majewski, Slawomir, Muñoz, Nubia, Myers, Evan R., Villa, Luisa L., Taddeo, Frank J., Roberts, Christine, Tadesse, Amha, Bryan, Janine, Maansson, Roger, Lu, Shuang, Vuocolo, Scott, Hesley, Teresa M., Saah, Alfred, Barr, Eliav, Haupt, Richard M.·2009·Cancer Prevention Research

Abstract

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6. Pap testing was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. Endpoints included high-grade cervical, vulvar, or vaginal lesions (CIN 2/3, VIN 2/3, or VaIN 2/3). Mean follow-up time was 42 months post dose 1. Vaccine efficacy against HPV 6/11/16/18–related high-grade cervical lesions in the per-protocol and intention-to-treat populations was 98.2% [95% confidence interval (95% CI), 93.3-99.8] and 51.5% (95% CI, 40.6-60.6), respectively. Vaccine efficacy against HPV 6/11/16/18–related high-grade vulvar and vaginal lesions in the per-protocol and intention-to-treat populations was 100.0% (95% CI, 82.6-100.0) and 79.0% (95% CI, 56.4-91.0), respectively. Efficacy in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results. The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1940-6207.capr-09-0031

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 328

Metadata

Authors
Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Olsson, S.-E., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, M., Steben, M., Bosch, F. X., Dillner, J., Joura, E. A., Majewski, S., Muñoz, N., Myers, E. R., Villa, L. L., Taddeo, F. J., Roberts, C., Tadesse, A., Bryan, J., Maansson, R., Lu, S., Vuocolo, S., Hesley, T. M., Saah, A., Barr, E., & Haupt, R. M.
Venue
Cancer Prevention Research
Published
2009-10-01
Volume
2
Issue
10
Pages
868-878
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
OpenAlex
W2168690984
Cited by
328
References
2
FWCI
19.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions. https://app.cochat.ai/papers/10.1158/1940-6207.capr-09-0031
The paper
Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Olsson, S.-E., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, M., Steben, M., . . . Haupt, R. M. (2009). A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-09-0031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.